Related Experiment Video

Updated: Aug 21, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

MYC as a key target for melanoma therapy

Manuel Lillo-Valero1, Mariano F Zacarías-Fluck1, Laura Soucek1,2,3,4

  • 1Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Instituto de Investigación Sanitaria Hospital Universitari Vall d'Hebron (IIS IR-HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Frontiers in Cell and Developmental Biology
|August 19, 2026
PubMed

Insights

MYC oncogene overexpression drives melanoma progression and impacts treatment response. Targeting MYC presents a promising therapeutic strategy for this aggressive skin cancer.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Melanoma is an aggressive skin cancer with increasing incidence and mortality.
  • Genetic drivers include BRAF, NRAS, NF1 mutations, or triple wildtype.
  • The MYC oncogene plays a critical role in various cancers, including melanoma.

Purpose of the Study:

  • To review the role of MYC in melanoma development and progression.
  • To examine MYC's relationship with targeted therapy and immunotherapy response and resistance.
  • To discuss current and future strategies for targeting MYC in melanoma.

Main Methods:

  • Literature review focusing on MYC's function in melanoma.
  • Analysis of genetic alterations leading to MYC deregulation.
  • Synthesis of data on therapeutic approaches targeting MYC.

Main Results:

  • MYC overexpression, via gene amplification or upstream signaling, is implicated in melanoma.
  • MYC activity influences response and resistance to melanoma treatments.
  • Various strategies are being explored to target MYC in melanoma.

Conclusions:

  • MYC is a significant driver of melanoma progression.
  • Understanding MYC's role is crucial for overcoming treatment resistance.
  • Targeting MYC holds potential as a future therapeutic avenue for melanoma patients.
Keywords:
MYCMYC inhibitionimmune therapymelanomaresistancetargeted therapy

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...